Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Sponsors
Nanjing Second Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Upon the judgment of the researcher, the subject or his legal representative can understand and comply with the requirements of the program, and voluntarily sign the informed consent; 2. According to the new type of coronavirus pneumonia diagnosis and treatment scheme (trial version 5) diagnostic criteria, accord with standard of new coronavirus pneumonia confirmed cases, clinical diagnostic criteria for classification to heavy (pneumonia severity index (PSI) III - V level, or arterial blood oxygen partial pressure (PaO2 / oxygen concentration (FiO2) (P/F) 300 mmHg) or less; 3. Aged 18 to 75 years male or female.
Exclusion criteria
Exclusion criteria: 1. The subject has a history of substance abuse (defined as the use of any illicit drug) or alcohol abuse within the first year of screening; 2. The subject suffers from active psychosis, which the researcher believes may interfere with their compliance with the study process; 3. Subjects are unable to participate in all study visits or follow study procedures; 4. The subject is a staff member of the research center or a member of his or her immediate family or relatives (such as spouse, parents, children, siblings) performing the study or the subject is compelled to agree to participate in the study; 5. Female subjects during lactation, or female subjects with positive results of serum pregnancy test during screening, or female subjects with positive results of urine pregnancy test before drug administration; 6. Have participated in other clinical research projects; 7. Subjects have hypersensitivity reactions or allergic reactions to the stem cell preparation or its components; 8. The subject suffers from any unstable or uncontrolled cardiovascular, lung, liver, kidney, gastrointestinal, urogenital, hematology, coagulation, immunology, endocrine/metabolic or other medical conditions that the investigator considers to interfere with the outcome of the study or endanger the subject's safety; 9. The subject has a history of malignant tumor; 10. Subjects have a history of severe neurological disorders, including stroke, multiple sclerosis, brain tumors, or neurodegenerative diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to disease recovery;Exacerbation (transfer to RICU) time; | — |
Countries
China
Contacts
Public ContactYongxiang Yi
Nanjing Second Hospital
Outcome results
None listed